retatrutide triple agonist clinical trial Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Triple hormone receptor agonist retatrutide

The results obtained revealed that GSTM1 null genotype and not GSTT1 null genotype is significantly associated with epilepsy and possibly involved in the development of the disease

tracking your own trends over 4 to 8 weeks provides a more accurate picture

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: the PIONEER 3 Randomized Clinical Trial

Avoid blood-thinning supplements (fish oil, vitamin E, garlic, ginger) for 48 hours before injection unless medically necessary

While D2-like dopamine receptor signaling seems to primarily regulate osteoclastogenesis and subsequent bone resorption, signaling via D1-like receptors was found to influence osteoblast activity